Roche to Face Significant Currency Headwinds -- Market Talk

Dow Jones04-10 19:17

1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:17 ET (11:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626419414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626419414","market":"nz","top_or_hot":-1,"title":"Roche to Face Significant Currency Headwinds -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche to Face Significant Currency Headwinds -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche to Face Significant Currency Headwinds -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 19:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626419414","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626419414","pubTimestamp":1775819820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RHHBY":"罗氏控股","03165":"华夏欧优股对冲"},"translate_title":"罗氏将面临重大货币阻力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:17 ET (11:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626419414","isCrawlerRequest":true}